Kisspeptin

Kisspeptin is a hormone made in the brain that controls the release of gonadotropin-releasing hormone (GnRH), which in turn drives LH, FSH, testosterone and estrogen. People born without working kisspeptin signaling do not go through normal puberty. Synthetic kisspeptin-10 and kisspeptin-54 are used in research studies; neither is an approved medicine.

They are different lengths of the same hormone, 10 and 54 amino acids, sharing the same 10-amino-acid active end. In mice, kisspeptin-54 lasted about 32 minutes in the blood and kisspeptin-10 about 4 minutes, and only kisspeptin-54 kept LH raised for long; it also appeared able to cross the blood-brain barrier. In men, kisspeptin-54 had a half-life of about 27.6 minutes. The early hormone, IVF and sexual-desire studies in people used kisspeptin-54. The FDA’s Category 2 compounding entry is for kisspeptin-10, so check which form a label names.

No. No kisspeptin product is approved for any use in the US. The FDA lists kisspeptin-10 in Category 2 of its 503A compounding policy, meaning it has “identified significant safety risks” and does not extend the policy that lets compounders use Category 1 substances. It has been there since September 29, 2023, and was still listed in the May 14, 2026 update. The next FDA compounding advisory committee meeting, planned before the end of February 2027, does not include kisspeptin on its agenda.

Only in research so far. In healthy men, kisspeptin raises LH, FSH and testosterone, and a 2026 study of 15 men kept LH and FSH raised for 12 days with daily 8-hour infusions under the skin. With round-the-clock infusion, though, LH and FSH fell back to placebo levels within 5 days. It is not an approved treatment for low testosterone or infertility. If you compete in sport, the World Anti-Doping Agency’s 2026 Prohibited List bans kisspeptin and its analogues in men at all times, as testosterone-stimulating peptides.

It changed how the brain responds to sexual cues in two small trials, but it is not a treatment. In 32 men with hypoactive sexual desire disorder (HSDD), a 75-minute intravenous infusion of kisspeptin-54 changed activity in the brain’s sexual-processing network and increased penile tumescence to sexual stimuli by up to 56% more than placebo; the men also reported more happiness about sex. In 32 premenopausal women with HSDD, it changed brain processing of sexual and facial attraction. Each was a single supervised visit with brain scans. A 2025 review, by an author with a related patent application, says delivery methods and other hurdles remain. For acquired, generalized HSDD in premenopausal women, the FDA has approved bremelanotide (Vyleesi), a different drug that acts on melanocortin receptors.

There is no single correct amount. The water only sets the concentration: mg in the vial ÷ mL of water = mg per mL. For example (numbers for illustration only, not a dose), 5 mg of kisspeptin-10 in 1 mL makes 5 mg/mL, so each unit on a U-100 insulin syringe holds 0.05 mg (50 mcg). The same vial in 2 mL makes 2.5 mg/mL, or 0.025 mg (25 mcg) per unit. More water means each unit holds less; less water means each unit holds more. The reconstitution calculator does this arithmetic for your vial. A 10 mg vial in the same volume is twice as concentrated. Because this product is not FDA-approved, no official label sets a water volume, and the contents of unapproved vials are not verified. Talk to a licensed prescriber or pharmacist before using any unapproved product.